Mar 12, 2020 / 08:30PM GMT
Operator
Greetings, and welcome to the Y-mAbs' Full Year 2019 Earnings Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Thomas Gad, Chairman and President. Please go ahead.
Thomas Gad - Y-mAbs Therapeutics, Inc. - Founder, Chairman, President & Head of Business Development and Strategy
Thank you, Ashley. Good afternoon, everyone, and thank you for joining us on this particular day. So 2019 was the year that we believe we made significant progress on our strategy and took steps that positioned us very well for 2020, as we worked to complete 2 BLA submissions and prepare for 2 potential product launches while significantly expanding our clinical activities.
We ended 2019 with $207 million in cash. And as you know, in late October, we completed a secondary offering led by Morgan Stanley, JPMorgan and BAML, in which we raised approximately net proceeds of $135 million to the company. These proceeds have further strengthened our balance sheet for the potential launch
Q4 2019 Y-mAbs Therapeutics, Inc Earnings Call Transcript
Mar 13, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers